Medical Disclaimer: We are not doctors or medical professionals, and this comparison is not medical advice. GLP-1 medications are prescription drugs requiring evaluation by a licensed healthcare provider, and they are not appropriate for everyone. Consult a qualified clinician before starting any medication or weight loss program. Affiliate disclosure: some links may earn us a commission at no extra cost to you — commissions never influence a ranking.
Hims and SkinnyRx sit at opposite poles of the GLP-1 telehealth market in 2026, and the contrast makes for the most instructive face-off in the category. Hims, post its March 2026 Novo Nordisk settlement, now sells FDA-approved brand-name medications wrapped in a household-name platform and a membership fee. SkinnyRx sells compounded formulations in more formats than anyone — including tablets and under-the-tongue drops — at cash-pay prices. Which philosophy fits you? Round by round.
The contenders
Hims — brand-name Wegovy® (pill and injectable) and tirzepatide options such as Zepbound®, prescribed via async telehealth. Published structure as of mid-2026: a Weight Loss Membership ($39 first month, then $149/month, billed separately, prescription not guaranteed) plus medication running roughly $249–$399/month self-pay — with a genuine insurance pathway that can cut brand-name costs dramatically for eligible commercially insured patients.
SkinnyRx — compounded semaglutide from about $199/month (injectable or sublingual) and compounded tirzepatide from about $299/month including tablets, consultations bundled, no membership fee, FSA/HSA accepted, no insurance. Compounded products are not FDA-approved — a distinction both this article and the FDA insist you internalize.
Round 1: The medication itself
No contest on regulatory standing: Hims dispenses FDA-approved products reviewed for safety, effectiveness, and manufacturing quality; SkinnyRx’s core lineup is compounded formulations that carry no such review — and SkinnyRx received an FDA warning letter in February 2026 over marketing language that blurred exactly that line (a labeling-claims issue, not a manufacturing-safety finding, but a fact you should weigh). SkinnyRx’s counterpunch is format: it’s one of the only platforms anywhere offering tirzepatide in tablet form and semaglutide sublingually — a real answer for the needle-averse, with the honest caveat that published evidence has generally favored injectable formulations.
Winner: Hims on the medication; SkinnyRx on the menu.
Round 2: True monthly cost
Self-pay, SkinnyRx wins easily: ~$199 all-in versus Hims’ medication-plus-membership stack that lands roughly $400+ for injectable Wegovy before any discounts. But flip one variable — commercial insurance — and the whole board inverts: reports indicate eligible insured patients combining coverage with the Novo Nordisk savings card through Hims can reach $0–$25/month for brand-name Wegovy, a price no compounded program can touch. Your insurance card, not the platforms, decides this round.
Winner: SkinnyRx for cash-pay; Hims for the commercially insured. Check your coverage before reading another review.
Round 3: Fine print and billing hygiene
Both have homework. Hims’ is structural: the $149/month membership is billed separately, auto-renews, and doesn’t guarantee a prescription — factor it into every price comparison. SkinnyRx’s is sharper-edged: the recurring complaint pattern involves multi-month prepaid bundles charged upfront when customers expected monthly billing, a no-refund-once-shipped policy, and phone-call cancellation. Its ~4.8-star Trustpilot record (4,000+ reviews) is legitimately strong; its BBB file tells the bundle-billing story. Screenshot both checkouts.
Winner: Hims, narrowly — a known fee beats a surprise bundle.
Round 4: Clinical model
Functionally similar, honestly: both are asynchronous, fast, no-required-labs models built for straightforward cases — convenience-first by design, with messaging support rather than structured coaching or specialist oversight. Neither is the right home for complex medical histories; both will tell a licensed provider your intake and let that provider decide. Hims’ scale and app polish edge it slightly; neither wins on depth.
Winner: Draw — and if clinical depth is your priority, your comparison set should be different programs entirely.
The verdict
- Best for the commercially insured and the FDA-approved-only crowd: Hims — brand-name medication, a real savings-card pathway, and big-company accountability, at the price of a stacked fee structure.
- Best for cash-pay and the needle-averse: SkinnyRx — the market’s widest format menu at aggressive prices, for shoppers who accept the compounded trade-off knowingly and read checkout pages like contracts.
- Who should skip both: anyone wanting labs, coaching, and hands-on monitoring, and anyone who hasn’t yet had the only conversation that matters — with a licensed healthcare provider about whether GLP-1 treatment is appropriate at all.
Shopping the wider field? Our four-program head-to-head covers TrimRX, Brightmeds, Wellorithm, and AltRx, and our compounded vs. brand-name face-off unpacks the fork in the road that this entire comparison sits on.
Pricing and program details reflect publicly available information as of mid-2026 and change frequently — verify current terms on each provider’s official website. One market note: Eden, another frequently searched program, has paused new-patient GLP-1 enrollment as of mid-2026. Wegovy®, Ozempic®, Zepbound®, and Mounjaro® are trademarks of their respective owners, which are not affiliated with this site.